Scleromyxedema

Research output: Contribution to journalArticle

Abstract

Purpose of review: To synthesize the current known data on pathogenesis and treatment of scleromyxedema. This review will also highlight the clinical presentation, systemic features and outcomes and distinguishing features between scleromyxedema and scleroderma, as a common mimic. Recent findings: Most recent publications have focused on describing treatment responses with novel therapies, with the majority of cases reporting success with intravenous immunoglobulin. However, other therapies suggest promise as well in case reports, including bortezomib, thalidomide and stem cell transplantation. There is little information on pathogenesis; however, focus has been on the relationship between the mucin deposition and the monoclonal immunoglobulins that are seen in almost all patients with scleromyxedema. Summary: Scleromyxedema is a rare mucinous deposition disorder that shares clinical features with scleroderma but has important distinguishing features in clinical presentation and major organ complications that should be recognized. Patients typically respond well to therapy as highlighted in several larger series, but poor outcomes are reported in a few cases.

Original languageEnglish (US)
Pages (from-to)658-662
Number of pages5
JournalCurrent Opinion in Rheumatology
Volume26
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Scleromyxedema
Therapeutics
Thalidomide
Intravenous Immunoglobulins
Stem Cell Transplantation
Mucins
Immunoglobulins

Keywords

  • Bortezomib
  • Intravenous immunoglobulin
  • Mucin
  • Scleromyxedema
  • Thalidomide

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Scleromyxedema. / Hummers, Laura.

In: Current Opinion in Rheumatology, Vol. 26, No. 6, 2014, p. 658-662.

Research output: Contribution to journalArticle

Hummers, Laura. / Scleromyxedema. In: Current Opinion in Rheumatology. 2014 ; Vol. 26, No. 6. pp. 658-662.
@article{cf4fd05da1fc4d7cb571de804320c165,
title = "Scleromyxedema",
abstract = "Purpose of review: To synthesize the current known data on pathogenesis and treatment of scleromyxedema. This review will also highlight the clinical presentation, systemic features and outcomes and distinguishing features between scleromyxedema and scleroderma, as a common mimic. Recent findings: Most recent publications have focused on describing treatment responses with novel therapies, with the majority of cases reporting success with intravenous immunoglobulin. However, other therapies suggest promise as well in case reports, including bortezomib, thalidomide and stem cell transplantation. There is little information on pathogenesis; however, focus has been on the relationship between the mucin deposition and the monoclonal immunoglobulins that are seen in almost all patients with scleromyxedema. Summary: Scleromyxedema is a rare mucinous deposition disorder that shares clinical features with scleroderma but has important distinguishing features in clinical presentation and major organ complications that should be recognized. Patients typically respond well to therapy as highlighted in several larger series, but poor outcomes are reported in a few cases.",
keywords = "Bortezomib, Intravenous immunoglobulin, Mucin, Scleromyxedema, Thalidomide",
author = "Laura Hummers",
year = "2014",
doi = "10.1097/BOR.0000000000000118",
language = "English (US)",
volume = "26",
pages = "658--662",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Scleromyxedema

AU - Hummers, Laura

PY - 2014

Y1 - 2014

N2 - Purpose of review: To synthesize the current known data on pathogenesis and treatment of scleromyxedema. This review will also highlight the clinical presentation, systemic features and outcomes and distinguishing features between scleromyxedema and scleroderma, as a common mimic. Recent findings: Most recent publications have focused on describing treatment responses with novel therapies, with the majority of cases reporting success with intravenous immunoglobulin. However, other therapies suggest promise as well in case reports, including bortezomib, thalidomide and stem cell transplantation. There is little information on pathogenesis; however, focus has been on the relationship between the mucin deposition and the monoclonal immunoglobulins that are seen in almost all patients with scleromyxedema. Summary: Scleromyxedema is a rare mucinous deposition disorder that shares clinical features with scleroderma but has important distinguishing features in clinical presentation and major organ complications that should be recognized. Patients typically respond well to therapy as highlighted in several larger series, but poor outcomes are reported in a few cases.

AB - Purpose of review: To synthesize the current known data on pathogenesis and treatment of scleromyxedema. This review will also highlight the clinical presentation, systemic features and outcomes and distinguishing features between scleromyxedema and scleroderma, as a common mimic. Recent findings: Most recent publications have focused on describing treatment responses with novel therapies, with the majority of cases reporting success with intravenous immunoglobulin. However, other therapies suggest promise as well in case reports, including bortezomib, thalidomide and stem cell transplantation. There is little information on pathogenesis; however, focus has been on the relationship between the mucin deposition and the monoclonal immunoglobulins that are seen in almost all patients with scleromyxedema. Summary: Scleromyxedema is a rare mucinous deposition disorder that shares clinical features with scleroderma but has important distinguishing features in clinical presentation and major organ complications that should be recognized. Patients typically respond well to therapy as highlighted in several larger series, but poor outcomes are reported in a few cases.

KW - Bortezomib

KW - Intravenous immunoglobulin

KW - Mucin

KW - Scleromyxedema

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=84927797646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927797646&partnerID=8YFLogxK

U2 - 10.1097/BOR.0000000000000118

DO - 10.1097/BOR.0000000000000118

M3 - Article

VL - 26

SP - 658

EP - 662

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 6

ER -